Gloria Dalla Costa, Vittorio Martinelli, Lucia Moiola, Francesca Sangalli, Bruno Colombo, Annamaria Finardi, Paola Cinque, Eva-Maria Kolb, Aiden Haghikia, Ralf Gold, Roberto Furlan, Giancarlo Comi
This study analyzed serum neurofilament light chains (NfL) in 2 European cohorts of 312 MS patients to investigate whether NfL are biomarkers of PML during natalizumab treatment. The cohort comprised 25 PML, 136 natalizumab-treated, and 151 untreated MS patients. Patients subsequently developing PML had similar NfL to other natalizumab-treated MS patients. At PML onset, NfL were 10-fold higher than in the pre-PML condition and in natalizumab-treated or untreated MS patients, and NfL continued to increase until onset of immune reconstitution inflammatory syndrome...
February 13, 2019: Annals of Neurology